OpenLB
Open Library of Bioscience
Advanced Search
Epigenetics
12, 2019;14 (12): 1164-1176.

Epidrugs: targeting epigenetic marks in cancer treatment.

Cristiana Libardi Miranda Furtado, Maria Claudia Dos Santos Luciano, Renan Da Silva Santos, Gilvan Pessoa Furtado, Manoel Odorico Moraes, Claudia Pessoa
Author Information
  1. Cristiana Libardi Miranda Furtado: Department of Surgery, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
  2. Maria Claudia Dos Santos Luciano: Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
  3. Renan Da Silva Santos: Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
  4. Gilvan Pessoa Furtado: Department of Biotechnology, Oswaldo Cruz Foundation , Fortaleza , Brazil.
  5. Manoel Odorico Moraes: Department of Surgery, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
  6. Claudia Pessoa: Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara , Fortaleza , Brazil.
PMID: 31282279 DOI: 10.1080/15592294.2019.1640546

Abstract

Growing evidence suggests that aberrant epigenetic regulation of gene function is strongly related to the genesis of cancer. Unlike genetic mutations, the ability to reprogram the epigenetic landscape in the cancer epigenome is one of the most promising target therapies in both treatment and reversibility of drug resistance. Epigenetic alterations in cancer development and progression may be the basis for the individual variation in drug response. Thus, this review focuses on the emerging area of pharmaco(epi)genomics, specifically highlighting epigenetic reprogramming during tumorigenesis and how epigenetic markers are targeted as a therapy (epidrugs) and the clinical implications of this for cancer treatment.

Keywords

Epigenetics cancer epidrugs pharmacology reprogramming treatment

References

  1. Gut. 2014 Apr;63(4):635-46 [PMID: 23704319]
  2. Nat Rev Genet. 2018 Feb;19(2):81-92 [PMID: 29033456]
  3. Cancer Lett. 2009 Aug 8;280(2):201-10 [PMID: 19181442]
  4. Cancer Treat Rev. 2016 Nov;50:35-47 [PMID: 27612280]
  5. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S198-S201 [PMID: 30393600]
  6. Nat Rev Genet. 2002 Jun;3(6):415-28 [PMID: 12042769]
  7. Cold Spring Harb Symp Quant Biol. 2004;69:67-70 [PMID: 16117634]
  8. Am J Stem Cells. 2011 Aug 19;1(1):59-74 [PMID: 23671798]
  9. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2888-96 [PMID: 20978174]
  10. Nature. 2004 May 27;429(6990):457-63 [PMID: 15164071]
  11. Nat Rev Clin Oncol. 2014 Mar;11(3):167-76 [PMID: 24492837]
  12. Arch Pharm Res. 2019 Feb;42(2):159-170 [PMID: 30806885]
  13. Mol Reprod Dev. 2010 Feb;77(2):105-13 [PMID: 19921744]
  14. Nature. 2017 Feb 23;542(7642):475-478 [PMID: 28192787]
  15. Cell. 2011 Mar 4;144(5):646-74 [PMID: 21376230]
  16. Biochem Biophys Res Commun. 2018 Jan 1;495(1):539-545 [PMID: 29050940]
  17. Oncogene. 2001 May 28;20(24):3139-55 [PMID: 11420731]
  18. Biomed Pharmacother. 2016 Oct;83:1032-1037 [PMID: 27541047]
  19. Cancer Cell. 2015 May 11;27(5):617-30 [PMID: 25965569]
  20. Mol Biol Rep. 2018 Dec;45(6):2935-2940 [PMID: 30311129]
  21. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):1-12 [PMID: 25384337]
  22. Genes Dev. 2015 Oct 1;29(19):2037-53 [PMID: 26404942]
  23. Genes (Basel). 2017 Jan 09;8(1): [PMID: 28075356]
  24. Oncotarget. 2016 Jun 28;7(26):40418-40436 [PMID: 27250026]
  25. Cancer Chemother Pharmacol. 2014 Oct;74(4):691-7 [PMID: 25062770]
  26. J Biomed Nanotechnol. 2015 Nov;11(11):1859-98 [PMID: 26554150]
  27. Cancer Res. 2016 Apr 1;76(7):1683-9 [PMID: 26988985]
  28. Pharmacol Ther. 2016 Jun;162:98-119 [PMID: 26808162]
  29. Mod Pathol. 2007 Jul;20(7):711-21 [PMID: 17464311]
  30. Leuk Res. 2012 Aug;36(8):1049-54 [PMID: 22472464]
  31. Biochim Biophys Acta. 2014 Aug;1839(8):728-36 [PMID: 24583555]
  32. Clin Rev Allergy Immunol. 2010 Aug;39(1):78-84 [PMID: 19662539]
  33. Curr Opin Pharmacol. 2017 Aug;35:48-56 [PMID: 28609681]
  34. Oncotarget. 2017 Jan 31;8(5):8189-8205 [PMID: 28029658]
  35. Expert Opin Drug Discov. 2017 Apr;12(4):345-362 [PMID: 28276705]
  36. Genes Dev. 2011 May 15;25(10):1010-22 [PMID: 21576262]
  37. Cell Oncol (Dordr). 2015 Feb;38(1):17-28 [PMID: 25113790]
  38. Mamm Genome. 2009 Sep-Oct;20(9-10):563-72 [PMID: 19830403]
  39. Cells. 2017 May 09;6(2): [PMID: 28486418]
  40. Biomark Res. 2017 Jan 20;5:1 [PMID: 28127428]
  41. Oncologist. 2005 Mar;10(3):176-82 [PMID: 15793220]
  42. Bioessays. 2003 Jun;25(6):577-88 [PMID: 12766947]
  43. Thorac Cancer. 2018 Jul;9(7):794-799 [PMID: 29737623]
  44. J Surg Res. 2006 Oct;135(2):317-22 [PMID: 16815451]
  45. PLoS One. 2012;7(5):e36980 [PMID: 22693562]
  46. Oncotarget. 2017 Dec 17;9(13):11414-11426 [PMID: 29541423]
  47. Nature. 1959 Jun 13;183(4676):1654-5 [PMID: 13666847]
  48. Epigenomics. 2016 Jan;8(1):9-12 [PMID: 26698294]
  49. Int J Cancer. 2012 Jul 1;131(1):18-29 [PMID: 21796622]
  50. J Biomed Sci. 2016 Nov 18;23(1):81 [PMID: 27863490]
  51. Biophys J. 2014 Nov 4;107(9):2141-50 [PMID: 25418099]
  52. Cancer Res. 2009 May 1;69(9):3802-9 [PMID: 19366799]
  53. Front Immunol. 2017 Feb 16;8:56 [PMID: 28261196]
  54. Trends Biochem Sci. 2010 Nov;35(11):618-26 [PMID: 20685123]
  55. Cancer Sci. 2018 Sep;109(9):2641-2650 [PMID: 29989289]
  56. Mol Cancer. 2016 May 17;15(1):39 [PMID: 27189224]
  57. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3971-5 [PMID: 4372599]
  58. Carcinogenesis. 2010 Jan;31(1):27-36 [PMID: 19752007]
  59. Int J Mol Sci. 2018 Jun 06;19(6): [PMID: 29882812]
  60. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7 [PMID: 17875987]
  61. J Cancer. 2016 Aug 15;7(13):1842-1855 [PMID: 27698924]
  62. Nat Rev Cancer. 2018 Jan;18(1):5-18 [PMID: 29170536]
  63. EBioMedicine. 2016 Oct;12:34-42 [PMID: 27720213]
  64. Br J Cancer. 2017 Mar 28;116(7):874-883 [PMID: 28222071]
  65. J Cell Physiol. 2018 Aug;233(8):5574-5588 [PMID: 29521426]
  66. Nat Med. 2011 Mar;17(3):330-9 [PMID: 21386836]
  67. J Hematol Oncol. 2014 Jan 23;7:11 [PMID: 24456586]
  68. J Med Genet. 2006 Jul;43(7):615-6 [PMID: 16236811]
  69. Dis Markers. 2007;23(1-2):1-3 [PMID: 17325422]
  70. Am J Med Genet C Semin Med Genet. 2010 Aug 15;154C(3):365-76 [PMID: 20803659]
  71. Hum Mol Genet. 2000 Sep 1;9(14):2075-83 [PMID: 10958646]
  72. BMB Rep. 2018 Nov;51(11):563-571 [PMID: 30158023]
  73. Adv Exp Med Biol. 2017;1008:199-222 [PMID: 28815541]
  74. Curr Cancer Drug Targets. 2016;16(9):773-788 [PMID: 26638884]
  75. Cancer Genet Cytogenet. 2005 Jan 1;156(1):31-6 [PMID: 15588853]
  76. Oncotarget. 2011 Aug;2(8):627-37 [PMID: 21896958]
  77. Cell Oncol (Dordr). 2017 Feb;40(1):21-32 [PMID: 27766591]
  78. Bioessays. 2018 Jan;40(1): [PMID: 29205437]
  79. Nat Rev Genet. 2006 Jan;7(1):21-33 [PMID: 16369569]
  80. Mol Cancer. 2015 Nov 04;14:184 [PMID: 26536864]
  81. Invest New Drugs. 2013 Oct;31(5):1192-200 [PMID: 23907406]
  82. Dev Biol. 2008 Jan 1;313(1):335-46 [PMID: 18048024]
  83. Am J Physiol Cell Physiol. 2010 Jun;298(6):C1280-90 [PMID: 20200206]
  84. Cell. 1975 Apr;4(4):379-86 [PMID: 164293]
  85. Cancer Res. 2016 Jul 1;76(13):3666-70 [PMID: 27325641]
  86. Expert Opin Investig Drugs. 2015;24(7):965-79 [PMID: 25936363]
  87. Nat Rev Genet. 2016 Sep 15;17(10):630-41 [PMID: 27629931]
  88. Drug Resist Updat. 2013 Jul-Nov;16(3-5):47-59 [PMID: 23757365]
  89. Mol Immunol. 2017 Jul;87:227-239 [PMID: 28511092]
  90. Nature. 2012 Apr 29;485(7397):201-6 [PMID: 22575960]
  91. Drug Resist Updat. 2011 Dec;14(6):280-96 [PMID: 21955833]
  92. Biomed Pharmacother. 2018 Oct;106:1668-1677 [PMID: 30170355]
  93. Anticancer Agents Med Chem. 2016;16(1):128-35 [PMID: 26278546]
  94. Curr Opin Genet Dev. 2009 Apr;19(2):127-34 [PMID: 19299119]
  95. Nature. 2016 Apr 21;532(7599):329-33 [PMID: 27027282]
  96. Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207 [PMID: 28992434]
  97. Proc Jpn Acad Ser B Phys Biol Sci. 2018;94(6):235-247 [PMID: 29887568]
  98. Cytotechnology. 2017 Aug;69(4):667-680 [PMID: 28321778]
  99. Nat Rev Drug Discov. 2018 Mar;17(3):183-196 [PMID: 29217837]
  100. Biomed Pharmacother. 2016 Dec;84:1393-1405 [PMID: 27802904]
  101. Hum Mol Genet. 2000 Oct;9(16):2395-402 [PMID: 11005794]
  102. Epigenetics. 2009 Jul 1;4(5):277-86 [PMID: 19617707]
  103. Oncologist. 2015 Sep;20(9):1084-91 [PMID: 26099743]
  104. Cancer Immunol Res. 2015 Dec;3(12):1375-85 [PMID: 26297712]
  105. BMC Cancer. 2015 May 26;15:430 [PMID: 26008690]
  106. Bioessays. 2010 Nov;32(11):949-57 [PMID: 21154865]
  107. Elife. 2013 Jun 25;2:e00747 [PMID: 23805382]
  108. Exp Ther Med. 2013 Apr;5(4):1143-1146 [PMID: 23599737]
  109. Int J Mol Sci. 2017 Oct 02;18(10): [PMID: 29036883]
  110. Genome Res. 2012 Feb;22(2):246-58 [PMID: 22156296]
  111. Cell. 2018 Nov 15;175(5):1228-1243.e20 [PMID: 30392959]
  112. BMC Cancer. 2016 Nov 7;16(1):857 [PMID: 27821078]
  113. J Clin Oncol. 2017 Apr 20;35(12):1341-1367 [PMID: 28148207]
  114. Clin Cancer Res. 2009 Aug 1;15(15):5002-7 [PMID: 19638460]
  115. Oncotarget. 2015 Oct 6;6(30):29161-77 [PMID: 26313360]
  116. Clin Epigenetics. 2017 May 30;9:59 [PMID: 28572863]
  117. J BUON. 2014 Oct-Dec;19(4):1111-20 [PMID: 25536624]

MeSH Term

Animals
Antineoplastic Agents
Epigenesis, Genetic
Epigenomics
Humans
Neoplasms
Pharmacogenetics

Chemicals

Antineoplastic Agents
Journal Article Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0cancerepigenetictreatmentdrugreprogrammingepidrugsGrowingevidencesuggestsaberrantregulationgenefunctionstronglyrelatedgenesisUnlikegeneticmutationsabilityreprogramlandscapeepigenomeonepromisingtargettherapiesreversibilityresistanceEpigeneticalterationsdevelopmentprogressionmaybasisindividualvariationresponseThusreviewfocusesemergingareapharmacoepigenomicsspecificallyhighlightingtumorigenesismarkerstargetedtherapyclinicalimplicationsEpidrugs:targetingmarksEpigeneticspharmacology

Similar Articles

Cited By